Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
  1. Home
  2. Publications
  3. Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Authors:
  • NZNingning Zhang
    Ningning Zhang
  • TLTian Liu
    Tian Liu
  • MLMing Luo
    Ming Luo
  • JHJihui Hao
    Jihui Hao
  • SQShukui Qin
    Shukui Qin
  • YZYanqiao Zhang
    Yanqiao Zhang
  • GWGang Wang
    Gang Wang
  • YCYajin Chen
    Yajin Chen
  • JZJingdong Zhang
    Jingdong Zhang
  • SGShanzhi Gu
    Shanzhi Gu
  • JNJunqi Niu
    Junqi Niu
  • GXGuijie Xin
    Guijie Xin

Open Access
Publisher website
Google Scholar
  • 1 August 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.29760296
Abstract
Supplementary Table S3. Density of various immune cells and their ratio to CD8+ cells as revealed by multiplex immunofluorescence.
Keywords
  • CLINICAL TRIAL RESULTS
  • PHASE I CLINICAL TRIALS
  • GASTROINTESTINAL CANCERS
  • LIVER CANCER
  • IMMUNOTHERAPY
  • COMBINATION IMMUNOTHERAPY
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.